Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effects of 5-aza-2′-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease

12 Aug 2003

Abstract excerpt

Fetal hemoglobin (HbF) decreases polymerization of sickle hemoglobin (HbS) and improves outcomes in sickle cell disease (SSD). Therefore, a therapeutic goal in SSD is pharmacologic reactivation of HbF. Silencing of the gamma-globin (HbF) gene is associated with DNA methylation. The cytosine analog 5-aza-2'-deoxycytidine (decitabine) hypomethylates DNA by inhibiting DNA methyltransferase. We examined if...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Epigenetics and DNA Methylation
Share to Hemoglobinopathies and Related Disorders
Share to Prenatal Screening and Diagnostics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 12907443
DOI: 10.1182/blood-2003-05-1738

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effects of 5-aza-2′-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell diseasePMID 12907443Read ↗

Reviewing the impact of hydroxyurea on DNA methylation and its potential clinical implications in sickle cell diseaseSemantic proximity Read ↗

Neither DNA hypomethylation nor changes in the kinetics of erythroid differentiation explain 5-azacytidine's ability to induce human fetal hemoglobinSemantic proximity Read ↗

A pilot study of subcutaneous decitabine in β-thalassemia intermediaSemantic proximity Read ↗

Epigenetic and molecular profiles of erythroid cells after hydroxyurea treatment in sickle cell anemiaSemantic proximity Read ↗

Hydroxyurea Treatment for Sickle Cell DiseaseSemantic proximity Read ↗

Genetic reversal of the globin switch concurrently modulates both fetal and sickle hemoglobin and reduces red cell sicklingSemantic proximity Read ↗

Fetal hemoglobin silencing in humansSemantic proximity Read ↗

Enhanced induction of fetal hemoglobin by the combination of decitabine with RN-1 in β-thalassemia/HbE erythroid progenitor cells.Semantic proximity Read ↗

MIR 29B mediates epigenetic mechanisms of HBG gene activationSemantic proximity Read ↗

Dimethyl fumarate increases fetal hemoglobin, provides heme detoxification, and corrects anemia in sickle cell diseaseSemantic proximity Read ↗

Individual red blood cell fetal hemoglobin quantification allows to determine protective thresholds in sickle cell diseaseSemantic proximity Read ↗

Therapeutic Approaches to Hemoglobin Switching in Treatment of HemoglobinopathiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.